Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Bank of Nova Scotia

Bank of Nova Scotia lessened its stake in Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) by 91.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,806 shares of the medical research company’s stock after selling 20,198 shares during the period. Bank of Nova Scotia’s holdings in Bio-Rad Laboratories were worth $893,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. HM Payson & Co. acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth about $28,000. Cambridge Trust Co. boosted its stake in shares of Bio-Rad Laboratories by 170.0% during the first quarter. Cambridge Trust Co. now owns 54 shares of the medical research company’s stock worth $30,000 after buying an additional 34 shares during the period. Parkside Financial Bank & Trust boosted its stake in shares of Bio-Rad Laboratories by 80.0% during the second quarter. Parkside Financial Bank & Trust now owns 54 shares of the medical research company’s stock worth $26,000 after buying an additional 24 shares during the period. Tcwp LLC acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth about $48,000. Finally, Rosenberg Matthew Hamilton boosted its stake in shares of Bio-Rad Laboratories by 65.0% during the second quarter. Rosenberg Matthew Hamilton now owns 99 shares of the medical research company’s stock worth $50,000 after buying an additional 39 shares during the period. Institutional investors and hedge funds own 64.33% of the company’s stock.

Bio-Rad Laboratories Trading Up 0.9 %

Shares of Bio-Rad Laboratories stock opened at $398.12 on Friday. Bio-Rad Laboratories, Inc. has a 12-month low of $344.63 and a 12-month high of $783.94. The company has a current ratio of 5.50, a quick ratio of 4.30 and a debt-to-equity ratio of 0.14. The stock has a market cap of $11.87 billion, a PE ratio of -1.97 and a beta of 0.92. The company has a 50-day moving average of $410.79 and a two-hundred day moving average of $475.91.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last issued its earnings results on Thursday, October 27th. The medical research company reported $2.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.01. Bio-Rad Laboratories had a negative net margin of 215.16% and a positive return on equity of 4.13%. The company had revenue of $680.10 million during the quarter, compared to analysts’ expectations of $685.50 million. During the same period last year, the company posted $3.71 earnings per share. The firm’s quarterly revenue was down 9.0% compared to the same quarter last year. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 14.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BIO shares. Credit Suisse Group decreased their target price on shares of Bio-Rad Laboratories from $715.00 to $640.00 and set an “outperform” rating for the company in a research note on Friday, October 28th. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, November 9th. Finally, TheStreet cut shares of Bio-Rad Laboratories from a “c” rating to a “d+” rating in a report on Thursday, October 27th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $680.00.

Bio-Rad Laboratories Company Profile

(Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Featured Stories

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.